Total Payments
$1.8M
2024 Payments
$100,152
Companies
72
Transactions
3,653
Medicare Patients
3,840
Medicare Billing
$391,648
Payment Breakdown by Category
Other$1.2M (68.6%)
Travel$312,954 (17.7%)
Consulting$180,628 (10.2%)
Food & Beverage$58,778 (3.3%)
Education$2,152 (0.1%)
Research$524.64 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 563 | 67.6% |
| Travel and Lodging | $312,954 | 783 | 17.7% |
| Consulting Fee | $180,628 | 92 | 10.2% |
| Food and Beverage | $58,778 | 2,183 | 3.3% |
| Honoraria | $17,120 | 13 | 1.0% |
| Education | $2,152 | 16 | 0.1% |
| Unspecified | $524.64 | 3 | 0.0% |
Payments by Type
General
$1.8M
3,650 transactions
Research
$524.64
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $436,135 | 511 | $0 (2024) |
| Amgen Inc. | $199,453 | 297 | $0 (2024) |
| Kyowa Kirin, Inc. | $181,092 | 184 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $105,387 | 113 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $101,311 | 183 | $0 (2022) |
| ACADIA Pharmaceuticals Inc | $76,644 | 136 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $65,648 | 91 | $0 (2019) |
| US WorldMeds, LLC | $62,948 | 164 | $0 (2020) |
| Acorda Therapeutics, Inc | $62,039 | 122 | $0 (2023) |
| EMD Serono, Inc. | $57,984 | 175 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $100,152 | 293 | Otsuka America Pharmaceutical, Inc. ($28,281) |
| 2023 | $130,257 | 322 | Kyowa Kirin, Inc. ($56,786) |
| 2022 | $188,320 | 377 | Kyowa Kirin, Inc. ($77,560) |
| 2021 | $121,563 | 343 | Kyowa Kirin, Inc. ($24,920) |
| 2020 | $147,840 | 397 | Amgen Inc. ($35,719) |
| 2019 | $300,081 | 563 | GENZYME CORPORATION ($98,843) |
| 2018 | $386,097 | 635 | GENZYME CORPORATION ($142,591) |
| 2017 | $393,649 | 723 | GENZYME CORPORATION ($169,354) |
All Payment Transactions
3,653 individual payment records from CMS Open Payments — Page 1 of 147
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $148.07 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: NEUROLOGY | ||||||
| 12/17/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $9.19 | General |
| Category: PSYCHIATRY | ||||||
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,736.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $12.36 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/25/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $28.61 | General |
| Category: Neurology | ||||||
| 11/25/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $3.19 | General |
| Category: Neuroscience | ||||||
| 11/18/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $18.71 | General |
| Category: NEUROLOGY | ||||||
| 11/18/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $2.04 | General |
| Category: Neuroscience | ||||||
| 11/12/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $59.03 | General |
| 11/12/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $18.11 | General |
| 11/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $7.59 | General |
| Category: Neurology | ||||||
| 11/11/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 11/08/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $63.06 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $55.18 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $27.48 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2024 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $22.56 | General |
| 11/08/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $12.38 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $22.76 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $20.99 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $4.24 | General |
| Category: PSYCHIATRY | ||||||
| 11/04/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $30.93 | General |
| Category: NEUROLOGY | ||||||
| 11/04/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $6.22 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Qualitative Clinician Interviews to Explore and Characterize How Clinicians Assess and Classify Agitation-Related Behaviors in Alzheimers Dementia | Avanir Pharmaceuticals, Inc. | $490.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 807 | 986 | $207,708 | $73,456 |
| 2022 | 10 | 931 | 1,205 | $259,315 | $98,603 |
| 2021 | 11 | 1,098 | 1,490 | $322,044 | $123,675 |
| 2020 | 10 | 1,004 | 1,348 | $273,833 | $95,913 |
Total Patients
3,840
Total Services
5,029
Medicare Billing
$391,648
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 271 | 342 | $45,486 | $27,823 | 61.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 265 | 333 | $36,297 | $17,158 | 47.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 55 | 92 | $22,632 | $6,612 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 47 | 47 | $19,317 | $6,156 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 47 | 48 | $6,384 | $3,716 | 58.2% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2023 | 39 | 39 | $40,014 | $3,418 | 8.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $8,961 | $3,104 | 34.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 20 | $3,880 | $2,446 | 63.0% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2023 | 13 | 13 | $22,230 | $1,883 | 8.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 23 | $2,507 | $1,140 | 45.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 319 | 429 | $56,709 | $35,797 | 63.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 301 | 394 | $42,656 | $22,385 | 52.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 81 | 81 | $33,106 | $12,451 | 37.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 65 | 133 | $32,718 | $10,295 | 31.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 46 | 46 | $14,130 | $5,502 | 38.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 32 | $6,190 | $4,278 | 69.1% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 44 | 44 | $45,144 | $4,250 | 9.4% |
| 95911 | Nerve conduction, 9-10 studies | Office | 2022 | 14 | 14 | $23,940 | $2,199 | 9.2% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 17 | 17 | $2,367 | $766.88 | 32.4% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 15 | 15 | $2,355 | $679.57 | 28.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 365 | 540 | $65,340 | $44,970 | 68.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 327 | 449 | $44,451 | $25,805 | 58.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 101 | 101 | $37,774 | $16,568 | 43.9% |
| 95886 | Needle measurement and recording of electrical activity of muscles of arm or leg complete study | Office | 2021 | 97 | 188 | $46,248 | $14,898 | 32.2% |
| 95909 | Nerve transmission studies, 5-6 studies | Office | 2021 | 71 | 71 | $72,846 | $7,641 | 10.5% |
About Dr. Lori Guyton, M.D
Dr. Lori Guyton, M.D is a Neurology healthcare provider based in Herrin, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/26/2005. The National Provider Identifier (NPI) number assigned to this provider is 1295725752.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lori Guyton, M.D has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $100,152 received in 2024. These payments were reported across 3,653 transactions from 72 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.2M).
As a Medicare-enrolled provider, Guyton has provided services to 3,840 Medicare beneficiaries, totaling 5,029 services with total Medicare billing of $391,648. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Herrin, IL
- Active Since 10/26/2005
- Last Updated 09/10/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1295725752
Products in Payments
- AUBAGIO (Drug) $234,080
- LEMTRADA (Drug) $198,198
- Aimovig (Biological) $157,731
- NOURIANZ (Drug) $102,513
- ACTHAR (Biological) $97,254
- Nourianz (Drug) $78,578
- NUPLAZID (Drug) $76,644
- INGREZZA (Drug) $71,842
- INBRIJA (Drug) $45,332
- AJOVY (Drug) $41,936
- ZEPOSIA (Drug) $40,098
- UBRELVY (Drug) $32,520
- TROKENDI XR (Drug) $31,984
- Ongentys (Drug) $31,960
- Xadago (Drug) $31,442
- REXULTI (Drug) $28,323
- APTIOM (Drug) $28,012
- NURTEC ODT (Drug) $27,896
- Rebif (Biological) $27,153
- APOKYN (Drug) $26,455
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.